ECSP14013328A - Preparacion de liberacion sostenida - Google Patents
Preparacion de liberacion sostenidaInfo
- Publication number
- ECSP14013328A ECSP14013328A ECSP14013328A ECSP14013328A EC SP14013328 A ECSP14013328 A EC SP14013328A EC SP14013328 A ECSP14013328 A EC SP14013328A EC SP14013328 A ECSP14013328 A EC SP14013328A
- Authority
- EC
- Ecuador
- Prior art keywords
- sustained release
- release preparation
- pioglitazone
- salt
- hours
- Prior art date
Links
- 239000003405 delayed action preparation Substances 0.000 title abstract 3
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 6
- 229960005095 pioglitazone Drugs 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000007922 dissolution test Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000012085 test solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011232302 | 2011-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14013328A true ECSP14013328A (es) | 2014-05-31 |
Family
ID=47178262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP14013328 ECSP14013328A (es) | 2011-10-21 | 2014-04-29 | Preparacion de liberacion sostenida |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9907789B2 (enExample) |
| EP (1) | EP2768487B1 (enExample) |
| JP (1) | JP6093762B2 (enExample) |
| KR (1) | KR20140081826A (enExample) |
| CN (1) | CN104039313A (enExample) |
| AP (1) | AP2014007645A0 (enExample) |
| AR (1) | AR088398A1 (enExample) |
| AU (1) | AU2012326976B2 (enExample) |
| BR (1) | BR112014008744A2 (enExample) |
| CA (1) | CA2852417A1 (enExample) |
| CL (1) | CL2014000992A1 (enExample) |
| CO (1) | CO6960544A2 (enExample) |
| CR (1) | CR20140213A (enExample) |
| DO (1) | DOP2014000077A (enExample) |
| EA (1) | EA201490840A1 (enExample) |
| EC (1) | ECSP14013328A (enExample) |
| IL (1) | IL232114A0 (enExample) |
| IN (1) | IN2014DN03169A (enExample) |
| MA (1) | MA35717B1 (enExample) |
| MX (1) | MX2014004679A (enExample) |
| NZ (1) | NZ624275A (enExample) |
| PE (1) | PE20141189A1 (enExample) |
| PH (1) | PH12014500856A1 (enExample) |
| SG (2) | SG10201700121YA (enExample) |
| TN (1) | TN2014000152A1 (enExample) |
| TW (1) | TW201323018A (enExample) |
| UA (1) | UA113858C2 (enExample) |
| UY (1) | UY34403A (enExample) |
| WO (1) | WO2013058409A1 (enExample) |
| ZA (1) | ZA201403103B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6093762B2 (ja) | 2011-10-21 | 2017-03-08 | 武田薬品工業株式会社 | 徐放性製剤 |
| SG11201401189WA (en) | 2012-04-20 | 2014-09-26 | Gilead Sciences Inc | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection |
| US20150141517A1 (en) * | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
| KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
| UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
| JP2023066053A (ja) * | 2021-10-28 | 2023-05-15 | 東和薬品株式会社 | 放出制御医薬組成物 |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| JPH0624959A (ja) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| EP0661045B1 (en) | 1992-09-18 | 2002-07-03 | Yamanouchi Pharmaceutical Co. Ltd. | Sustained-release hydrogel preparation |
| JPH06316517A (ja) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| WO1998056359A2 (de) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Zusammensetzungen, die die wirkstofffreisetzung verzögern |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| EP1413315A4 (en) | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | DRUGS WITH CONTINUOUS RELEASE |
| KR20050053677A (ko) | 2002-09-20 | 2005-06-08 | 안드렉스 랩스 엘엘씨 | 비구아나이드와 티아졸리디네디온 유도체를 함유한 약제학적 투여형태 |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| IN192749B (enExample) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| US8980322B2 (en) | 2003-03-17 | 2015-03-17 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| JP4933033B2 (ja) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| JP2005015477A (ja) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| BRPI0410555A (pt) | 2003-06-06 | 2006-06-20 | Takeda Pharmaceutical | preparação sólida |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| WO2005099760A1 (ja) | 2004-04-14 | 2005-10-27 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| BRPI0514416A (pt) | 2004-08-31 | 2008-06-10 | Pfizer Prod Inc | formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade |
| KR20080058413A (ko) | 2005-09-22 | 2008-06-25 | 에스비 팜코 푸에르토 리코 인크. | Ａｐｏｅ4 음성 환자에서의 인지 기능의 개선을 위한ｐｐａｒ-감마 작동제 |
| WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
| RU2426530C2 (ru) | 2005-12-22 | 2011-08-20 | Такеда Фармасьютикал Компани Лимитед | Твердый препарат |
| KR101455741B1 (ko) | 2006-03-30 | 2014-10-28 | 니폰 조키 세야쿠 가부시키가이샤 | 고형 의약 제제 |
| JP2009534292A (ja) | 2006-04-27 | 2009-09-24 | 武田薬品工業株式会社 | 塩酸ピオグリタゾンを有するアンジオテンシンｉｉ拮抗薬の医薬組成物 |
| AU2008213744B2 (en) | 2007-02-09 | 2013-12-05 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| CN101269040A (zh) | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮缓释滴丸及其制备方法 |
| US8445190B2 (en) | 2008-09-30 | 2013-05-21 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| WO2011049309A2 (ko) | 2009-10-09 | 2011-04-28 | 영진약품공업 주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| JP2011232302A (ja) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | 画像検査方法及び画像検査装置 |
| CN101884627B (zh) | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | 盐酸吡格列酮胃内滞留缓释片及其制备方法 |
| EP3106165B1 (en) | 2011-01-10 | 2019-02-27 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
| JP6093762B2 (ja) | 2011-10-21 | 2017-03-08 | 武田薬品工業株式会社 | 徐放性製剤 |
| KR20160056691A (ko) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | 이차전지 |
-
2012
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/ja not_active Expired - Fee Related
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en not_active Ceased
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/es unknown
- 2012-10-19 TW TW101138592A patent/TW201323018A/zh unknown
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/es not_active Application Discontinuation
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/xx unknown
- 2012-10-19 UA UAA201405332A patent/UA113858C2/uk unknown
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/zh active Pending
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/pt not_active IP Right Cessation
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/ko not_active Ceased
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
- 2012-10-19 AR ARP120103908A patent/AR088398A1/es unknown
- 2012-10-19 EA EA201490840A patent/EA201490840A1/ru unknown
- 2012-10-19 UY UY0001034403A patent/UY34403A/es not_active Application Discontinuation
- 2012-10-19 PH PH1/2014/500856A patent/PH12014500856A1/en unknown
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/es unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/es unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/es unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/es unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/es unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14013328A (es) | Preparacion de liberacion sostenida | |
| AR132148A2 (es) | Método para mejorar la solubilidad de un compuesto poco soluble o insoluble en agua contenido en una formulación farmacéutica | |
| DOP2012000261A (es) | Formulaciones de insulina de accion prolongada | |
| CL2015000574A1 (es) | Formulaciones acuosas estables de adalimumab. | |
| CO7091182A2 (es) | Inhibidores de beta-lactamasa isoxazol | |
| GT201200322A (es) | Derivados de carbamato de hexafluoroisoprofilo, su preparacion y su aplicacion en terapeutica | |
| IN2014MN02213A (enExample) | ||
| PE20170306A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| MX358716B (es) | Composiciones estables para el cuidado bucal que comprenden un aminoácido básico , una sal de estroncio y una fuente de ion fluoruro y usos de las mismas. | |
| EA201391212A1 (ru) | Новые применения хлорида холина в агрохимических препаратах | |
| BR112012027545A2 (pt) | composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo | |
| CR20140053A (es) | Formulaciones de ácido desoxicólico y sales del mismo | |
| ECSP11011001A (es) | Composición farmacéutica sólida | |
| CL2012003488A1 (es) | Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias. | |
| TN2012000516A1 (en) | Stable ready to use injectable paracetamol formulation | |
| ECSP15003613A (es) | Formulación transdérmica que contiene inhibidores de cox | |
| EA201792122A1 (ru) | Кристаллическое соединение как ингибитор фермента семикарбазидчувствительной аминоксидазы (ssao) | |
| UY31057A1 (es) | Formulaciones de aminoacido n-halogenado que contiene acido alifatico | |
| TR201009399A2 (tr) | Hızlı çözünen efervesan rosuvastatin formülasyonları. | |
| AR067498A1 (es) | Composicion farmaceutica estable de una sal hidrosoluble de vinorrelbina | |
| PE20150022A1 (es) | Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis | |
| CO6630144A2 (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
| CL2010001172A1 (es) | Composicion farmaceutica solida termoestable que comprende un ingrediente farmaceutico activo de permeabilidad deficiente y al menos una sustancia mejoradora de la permeabilidad, incorporada en forma termoestable en una matriz soluble en agua de un portador soluble en agua; y un proceso para prepararla. | |
| IN2013MU03543A (enExample) | ||
| TR201203085A2 (tr) | Sefetamet ve klavulanik asit içeren bileşimler. |